<SEC-DOCUMENT>0001689548-25-000110.txt : 20251105
<SEC-HEADER>0001689548-25-000110.hdr.sgml : 20251105
<ACCEPTANCE-DATETIME>20251105080345
ACCESSION NUMBER:		0001689548-25-000110
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251105
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251105
DATE AS OF CHANGE:		20251105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Praxis Precision Medicines, Inc.
		CENTRAL INDEX KEY:			0001689548
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39620
		FILM NUMBER:		251451877

	BUSINESS ADDRESS:	
		STREET 1:		99 HIGH STREET, 30TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-300-8460

	MAIL ADDRESS:	
		STREET 1:		99 HIGH STREET, 30TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>prax-20251105.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a4f1ae67-d988-4f24-ae38-f7259ec2497a,g:8700ce9c-3d8e-4a52-bfbb-c25d99f9eca4,d:ed68c8d938964ba39108d96c222023da-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>prax-20251105</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001689548</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="prax-20251105.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-05</xbrli:startDate><xbrli:endDate>2025-11-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ied68c8d938964ba39108d96c222023da_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.00pt"><tr><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:148.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.00pt"><tr><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:148.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 5, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">PRAXIS PRECISION MEDICINES,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.00pt"><tr><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:148.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39620</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-5195942</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Praxis Precision Medicines, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">99 High Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">30th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">300-8460</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.00pt"><tr><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:148.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:157.00pt"/><td style="width:1.0pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:2.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:2.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:2.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:2.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:38.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Trade</span></div><div style="margin-bottom:1pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange</span></div><div style="margin-bottom:1pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">on which registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common&#160;Stock,&#160;$0.0001&#160;par value&#160;per&#160;share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">PRAX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="ied68c8d938964ba39108d96c222023da_7"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 5, 2025, Praxis Precision Medicines, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended September 30, 2025. A copy of the press release containing these announcements is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the &#8220;Current Report&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in Item 2.02 of this Current Report and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall any of it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="ied68c8d938964ba39108d96c222023da_16"></div><div style="-sec-extract:summary;margin-bottom:0.05pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Exhibit</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="praxisq32025pr.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="praxisq32025pr.htm">Press Release, dated November 5, 2025</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ied68c8d938964ba39108d96c222023da_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PRAXIS PRECISION MEDICINES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;5, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Marcio Souza</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marcio Souza</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>praxisq32025pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7eeeea88acba4c98925376e05e10460d_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:152px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET)&#59; Pre-NDA meeting with FDA scheduled for Q4 2025</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Plans to accelerate the development of relutrigine in SCN2A and SCN8A DEE patients after comprehensive Type B meeting with FDA</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Recruitment completed for POWER1 study of vormatrigine in focal onset seizures, with topline results expected in 1H 2026 </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">POWER2 study started, with enrollment expected to complete in 2H 2026</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%">Pro forma cash and investments of approximately $956 million, including proceeds from October 2025 public offering, fund operations into 2028</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">BOSTON, November 5, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Praxis Precision Medicines, Inc. (NASDAQ&#58; PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the third quarter 2025.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;It&#8217;s been a monumental few months for us at Praxis, culminating in the first ever successful Phase 3 program of an investigational drug in ET, with both studies in the Essential3 program meeting their primary endpoints. Ulixacaltamide demonstrated significant improvements in symptoms that are not only clinically meaningful but also change patients&#8217; lives. We have been granted a pre-NDA meeting with the FDA and look forward to discussing Praxis&#8217; first NDA submission,&#8221; said Marcio Souza, president and chief executive officer. &#8220;Leveraging our breakthrough therapy designation for relutrigine, we completed comprehensive discussions with the FDA to perform an interim analysis of our EMBOLD study in Q4 which, if successful, supports another potential NDA submission for relutrigine in SCN2A&#47;8A DEEs in early 2026. For our vormatrigine program, following the positive results from the first cohort of the RADIANT study, we have now completed recruitment for POWER1 with expected readout in the first half of 2026, and POWER2 is underway and planning to be fully enrolled in the second half of 2026. With the recently completed public offering, we are well-positioned to continue executing across our robust portfolio as we prepare for our first commercial launch, establishing Praxis as the leader in innovative therapies for CNS disorders.&#8221;</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Recent Highlights and Anticipated Milestones</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Cerebrum&#8482; Small Molecule Platform</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:12.53pt">Ulixacaltamide for Essential Tremor (ET)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> ET is the largest movement disorder affecting approximately seven million people in the U.S.  In October 2025, Praxis announced the positive results from the Essential3 program &#8211; the first positive Phase 3 program for a drug in ET. During the recruitment phase of the trial, which started in November 2023, over 200,000 patients demonstrated interest in participating in the study, underscoring the unmet need and size of the opportunity. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Study 1 (placebo-controlled, parallel group) met its primary and all secondary endpoints&#58;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Patients treated with ulixacaltamide in Study 1 showed a mean improvement from baseline in the modified Activities of Daily Living 11 (mADL11) at Week 8, the pre-specified primary endpoint, of 4.3 points (p&#60;0.0001). </font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The improvement in mADL11 was observed as early as Week 2 and was sustained throughout Week 12.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">All key-secondary endpoints were met, including rate of disease improvement, PGI-C and CGI-S at Week 8 showing statistically significant improvement with ulixacaltamide vs placebo (p&#60;0.001).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Study 2 (randomized withdrawal study) met its primary endpoint and first secondary endpoint&#58;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Primary endpoint of percentage of patients maintaining response was met with 55% of patients on ulixacaltamide vs 33% of patients on placebo maintaining their response (p&#61;0.037).</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The first key secondary endpoint of rate of disease improvement during the randomized withdrawal period also demonstrated superior effect in patients on ulixacaltamide vs placebo (p&#61;0.0042).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Additional pre-specified analyses were performed, further confirming the positive effect of ulixacaltamide&#58;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The first analysis combined patients treated with ulixacaltamide in Studies 1 and 2 and compared them to patients treated with placebo in Study 1. The analysis showed a 4.3 point improvement in mADL11 at Week 8 for the combined Studies 1 and 2 ulixacaltamide groups vs. Study 1 placebo (p&#60;0.0001).</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">In the second analysis, there was a 4.2 point improvement in mADL11 at Week 8 for the Study 2 ulixacaltamide group vs Study 1 placebo (p&#60;0.0001), respectively. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Ulixacaltamide was generally well tolerated with a safety profile consistent with previous trials and no drug-related serious adverse events.</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Pre-NDA meeting with the FDA was granted and is scheduled for the fourth quarter of 2025.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:12.53pt">Vormatrigine for FOS and Generalized Epilepsy&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Vormatrigine is the most potent sodium-channel modulator ever designed to precisely target the hyperexcitable state of sodium-channels in adult common epilepsies.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">In August 2025, Praxis shared positive results from the first cohort of the RADIANT study evaluating patients with FOS&#58;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">There was a rapid and sustained response, with approximately 60% of patients achieving 50% response in the study.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Vormatrigine was generally well tolerated and continues to demonstrate a favorable safety profile.</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Additional data were presented at the 36</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> International Epilepsy Congress highlighting &#91;poster&#93;. Praxis is planning to present additional results at the upcoming American Epilepsy Society Annual Meeting in December 2025.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The POWER1 Phase 2&#47;3 registrational study for FOS has completed recruitment, with topline readout expected in the first half of 2026.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The POWER2 Phase 3 registrational study for FOS has started and is expected to be fully enrolled in the second half of 2026.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The POWER3 study to evaluate vormatrigine as a standalone agent is expected to initiate in the first half of 2026.</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The overall ENERGY program recruitment initiative, including the EMPOWER study, has attracted approximately 20,000 patients in the US with epilepsy and continues to support patient identification for the epilepsy studies.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:12.53pt">Relutrigine for Developmental and Epileptic Encephalopathies (DEEs)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> Relutrigine is Praxis&#8217; second sodium channel modulator designed to precisely target the hyperexcitable state of sodium-channels, with therapeutic potential across developmental epilepsies.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Following a comprehensive Type B meeting, and recent meeting minutes and written advice on the protocol and statistical analysis plan, it has reached alignment with the FDA on several aspects of the relutrigine program in SCN2A and SCN8A DEEs, including the use of the ongoing EMBOLD study to serve as the basis of substantial evidence of effectiveness for the NDA submission. The FDA agreed that Praxis&#8217; proposed interim analysis, if positive, may serve as the basis of the NDA submission in early 2026. The interim analysis is planned to be conducted in the fourth quarter of 2025.Relutrigine is also being investigated in patients across all DEEs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">in the EMERALD trial. EMERALD is a registrational, 16-week, placebo-controlled study evaluating the efficacy and safety of relutrigine in reducing seizures in patients diagnosed with developmental epilepsies. </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Enrollment for the EMERALD study began in the third quarter of 2025 and is expected to be complete in the second half of 2026, receiving strong interest in the geographies where it is planned.  Assuming successful conclusion of the EMBOLD study and subsequent NDA approval, if positive, the EMERALD study would serve as the basis for an sNDA by 2027. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:125%">Solidus&#8482; Antisense Oligonucleotide (ASO) Platform</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;padding-left:12.53pt">Elsunersen for early-seizure-onset SCN2A DEE&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> SCN2A GoF-DEE is a rare, genetic epilepsy characterized by early-onset seizures and severe impact on development. Elsunersen is currently being evaluated in two registrational studies&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The EMBRAVE Part A Phase 1&#47;2 study is on track for topline results in the first half of 2026.</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">The EMBRAVE3 registrational study for SCN2A GoF-DEE is recruiting and expected to complete in 2026.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Praxis remains on track to nominate a development candidate for each of its early stage ASO therapeutic initiatives in the first half of 2026&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">PRAX-080&#58; Focused on targeting PCDH19 mosaic expression disorder.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">PRAX-090&#58; Designed to address SYNGAP1 loss-of-function (LoF) mutations, a leading cause of severe intellectual disability and epilepsy in DEEs.</font></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">PRAX-100&#58; Targeting SCN2A LoF mutations, the predominant genetic link to de novo autism spectrum disorders.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Third Quarter 2025 Financial Results&#58;</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As of September 30, 2025, Praxis had $389.2 million in cash, cash equivalents and marketable securities, compared to $469.5 million in cash, cash equivalents and marketable securities as of December 31, 2024. The decrease of $80.3 million is primarily attributable to cash used in operating activities, partially offset by net proceeds from at-the-market offerings of common stock. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In October 2025, Praxis announced the closing in October 2025 of an underwritten public offering of common stock and pre-funded warrants to purchase common stock, generating net proceeds of approximately $567.0 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Praxis. The Company&#8217;s cash, cash equivalents and marketable securities as of September 30, 2025, together with the proceeds from the October 2025 public offering, are expected to fund operations into 2028.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Praxis did not recognize any collaboration revenue during the three months ended September 30, 2025, compared to $0.3 million during the three months ended September 30, 2024. The decrease of $0.3 million is related to its Option and License Agreement with UCB. In December 2024, UCB exercised its option to in-license global development and commercialization rights for a KCNT1 small molecule development candidate, and as such, Praxis has no further research service obligations under the terms of the Option and License Agreement.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Research and development expenses were $65.8 million for the three months ended September 30, 2025, compared to $41.9 million for the three months ended September 30, 2024. The increase in research and development expenses of $23.9 million was primarily attributable to an increase of $21.7 million in Praxis&#8217; Cerebrum&#8482; platform and an increase of $1.9 million in Praxis&#8217;s Solidus&#8482;. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">General and administrative expenses were $12.6 million for the three months ended September 30, 2025, compared to $15.3 million for the three months ended September 30, 2024. The decrease in general and administrative expenses of approximately $2.7 million was primarily attributable to a decrease of $2.6 million in personnel-related costs.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Praxis reported a net loss of $73.9 million for the three months ended September 30, 2025, including $7.4 million of stock-based compensation expense, compared to $51.9 million for the three months ended September 30, 2024, including $12.4 million of stock-based compensation.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As of September 30, 2025, Praxis had 21.2 million shares of common stock outstanding.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Ulixacaltamide</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide, the most advanced program within Praxis&#8217; Cerebrum&#8482; small molecule platform is currently being evaluated in essential tremor (ET) - the largest movement disorder affecting approximately seven million people in the U.S.  In October 2025, Praxis announced positive results from the Essential3 program (NCT06087276), with ulixacaltamide showing statistically significant, durable, improvement in modified activities of daily living 11 (mADL11), as well as significant improvements in rate of disease improvement over 12 weeks, PGI-C and CGI-S. A pre-NDA meeting with the FDA has been scheduled for Q4 2025. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Vormatrigine (PRAX-628)</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Vormatrigine is a next-generation, functionally selective small molecule targeting the hyperexcitable state of sodium-channels in the brain that is currently being developed as a once daily, oral treatment for adult focal onset seizures and generalized epilepsy. Preclinical data demonstrates vormatrigine is differentiated from standard of care, with the potential to be best-in-class for focal epilepsy. In vitro, vormatrigine has demonstrated superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of vormatrigine have demonstrated unprecedented potency in the maximal electroshock seizure (MES) model, a highly predictive translational model for efficacy in focal epilepsy. Data from the first cohort of patients in the RADIANT study demonstrated a robust seizure reduction and generally safe and well tolerated profile. To learn more about the POWER1 study, please visit POWER1 study.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Relutrigine (PRAX-562)</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Relutrigine is a first-in-class small molecule in development for the treatment of developmental and epileptic encephalopathies (DEEs) as a preferential inhibitor of persistent sodium current, shown to be a key driver of seizure symptoms in severe DEEs. Relutrigine&#8217;s mechanism of precision sodium channel (NaV) modulation is consistent with superior selectivity for disease-state NaV channel hyperexcitability. In vivo studies of relutrigine have demonstrated dose-dependent inhibition of seizures up to complete control of seizure activity in SCN2A, SCN8A and other DEE mouse models. Relutrigine has been generally well-tolerated in three Phase 1 studies and has demonstrated biomarker changes indicative of NaV channel modulation. Data from cohort 1 of the Phase 2 EMBOLD study demonstrated a well-tolerated, robust, short- and long-term improvement in motor seizures in a heavily pre-treated population, alongside maintained seizure freedom in some patients with SCN2A- and SCN8A-DEE. Relutrigine has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the FDA for the treatment of SCN2A-DEE, SCN8A-DEE and Dravet syndrome&#59; as well as Breakthrough Therapy Designation (BTD), and ODD from the European Medicines Agency for the treatment of SCN2A-DEE and SCN8A-DEE. To learn more about the EMERALD and EMBOLD studies, please visit ResilienceStudies.com.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Elsunersen (PRAX-222)</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Elsunersen is an antisense oligonucleotide (ASO) designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-seizure-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations. In vitro studies of elsunersen have demonstrated reduction in both SCN2A gene expression and protein levels. In vivo, elsunersen has demonstrated significant, dose-dependent reduction in seizures, improvement in behavioral and locomotor activity and increased survival in SCN2A mouse models, with potential to be the first disease-modifying treatment for SCN2A-DEE. Elsunersen has received ODD and RPDD from the FDA, and ODD and PRIME designations from the European Medicines Agency for the treatment of SCN2A-DEE. The elsunersen program is ongoing under a collaboration with Ionis Pharmaceuticals, Inc., and RogCon, Inc. To learn more about the EMBRAVE study, please visit https&#58;&#47;&#47;www.embravestudy.com&#47;.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">About Praxis</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum&#8482;, and antisense oligonucleotide (ASO) platform, Solidus&#8482;, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter&#47;X.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Forward-Looking Statements</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis&#8217; future expectations, plans and prospects, including, without limitation, statements regarding the anticipated timing of our clinical trials, the development of our product candidates and plans to initiate new clinical programs, the anticipated timing of regulatory submissions and interactions and our projected cash runway, as well as other statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;endeavor,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or &#8220;would&#8221; and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation&#58; uncertainties inherent in clinical trials&#59; preliminary analyses from ongoing studies differing materially from final data from preclinical studies and completed clinical trials&#59; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities&#59; regulatory approvals to conduct trials&#59; and other risks concerning Praxis&#8217; programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2024 and as updated in the Quarterly Report on Form 10-Q for the period ended June 30, 2025, as well as other filings made with the Securities and Exchange Commission. Although Praxis&#8217; forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.</font></div><div style="margin-bottom:5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investor Contact&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8239;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Praxis Precision Medicines</font><font style="color:#626262;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8239;&#8239;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">investors&#64;praxismedicines.com&#8239;&#8239;&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">857-702-9452</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dan Ferry</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life Science Advisors</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Daniel&#64;lifesciadvisors.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">617-430-7576</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">PRAXIS PRECISION MEDICINES, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">(Amounts in thousands) </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:145%">(Unaudited)</font></div><div style="margin-bottom:8pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:71.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.555%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">September 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">149,527&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">215,372&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Marketable securities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">239,638&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">254,156&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">6,687&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">11,805&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">174&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">230&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">362&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1,131&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">416&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">396,388&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">483,110&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Liabilities and stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">30,819&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">12,528&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Accrued expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">21,628&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">23,763&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">436&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1,369&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Common stock</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1,394,088&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1,281,522&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Accumulated other comprehensive gain</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">654&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 20.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(1,051,097)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(836,740)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Total liabilities and stockholders' equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">396,388&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">483,110&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">PRAXIS PRECISION MEDICINES, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">(Amounts in thousands, except share and per share amounts) </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:700;line-height:125%">(Unaudited)</font></div><div style="margin-bottom:8pt;padding-right:-18.01pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:42.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.65pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Three Months Ended</font></div><div style="margin-bottom:8pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.65pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Nine Months Ended</font></div><div style="margin-bottom:8pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Collaboration revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">302&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1,090&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">65,797&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">41,881&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">189,609&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">96,125&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">12,562&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">15,256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">39,545&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">41,174&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">78,359&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">57,137&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">229,154&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">137,299&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(78,359)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(56,835)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(229,154)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(136,209)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Other income&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4,425&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">14,797&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">12,069&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Total other income</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4,425&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4,925&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">14,797&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">12,069&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">(73,934)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">(51,910)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">(214,357)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">(124,140)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Net loss per share attributable to common stockholders, basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">(3.36)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">(2.75)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">(9.97)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:145%">(7.21)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Weighted average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">21,977,268</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">18,884,562</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">21,506,021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">17,210,604</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>prax-20251105.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a4f1ae67-d988-4f24-ae38-f7259ec2497a,g:8700ce9c-3d8e-4a52-bfbb-c25d99f9eca4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:prax="http://praxismedicines.com/20251105" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://praxismedicines.com/20251105">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prax-20251105_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prax-20251105_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://praxismedicines.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>prax-20251105_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a4f1ae67-d988-4f24-ae38-f7259ec2497a,g:8700ce9c-3d8e-4a52-bfbb-c25d99f9eca4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_af93fbbe-ba55-42a9-8ff1-d585d3dbe795_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3a689974-69e5-4ae0-8432-7745873d282e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c5ec856c-ff0c-4357-896e-51a2156340a7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d03c59db-afae-4f3b-b682-795d4751667b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a8ca9f55-ce6f-44e0-881f-7d95203f6692_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_76fb485d-c461-48a8-8dd7-931fdcd40b42_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d0dd6a9c-9251-42d2-a47f-b2a1a835ac26_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_c91a1677-6993-4f52-a368-57e51af6569a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_861009d2-6eb6-4f29-b3a6-e382cb54a329_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_415ee458-be56-44f6-ba20-3c962303ba7a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_632ff5cb-fab9-4b8a-ae7a-51deccd0c26e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_96c03155-8ec5-4a63-b96b-0fa4cab459bc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_30f7dfc4-7f57-4683-bed0-bc0e494c581f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_de683d2a-aea3-45bc-be10-5538c968dbc0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_efbd2358-13a8-4951-96da-228aaaff88a2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_59c6229d-d6d3-4924-a009-88028e31bea8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_290837f5-5cb8-432d-9873-9361fbf46343_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fe1db5d1-8614-4d55-8c85-3b4e2ade1d5c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_58902a8d-8469-4005-b32d-311ddeb2e866_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_008e2425-8a76-458f-bde9-93ab5cb9c56a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_1c77f9b9-07a3-4106-a8b6-118053c8faad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6cf0d280-ea8e-4d1a-8d3e-c40f1dd1bf62_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5010cb35-9f19-4f6b-9bfb-426c96bbd886_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>prax-20251105_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:a4f1ae67-d988-4f24-ae38-f7259ec2497a,g:8700ce9c-3d8e-4a52-bfbb-c25d99f9eca4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://praxismedicines.com/role/Cover" xlink:type="simple" xlink:href="prax-20251105.xsd#Cover"/>
  <link:presentationLink xlink:role="http://praxismedicines.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fb0cc236-5a48-460d-bf63-900af9c8450e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_DocumentType_fb0cc236-5a48-460d-bf63-900af9c8450e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_49ea58b8-ee25-44d0-917e-b66e6fdffe8c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_DocumentPeriodEndDate_49ea58b8-ee25-44d0-917e-b66e6fdffe8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_829f19af-9655-4e7a-a573-16e19b0256d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityRegistrantName_829f19af-9655-4e7a-a573-16e19b0256d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5a7cbaa7-43ed-4b38-ab8d-60e23b642b45" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_AmendmentFlag_5a7cbaa7-43ed-4b38-ab8d-60e23b642b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2c9a68d4-5d2e-4024-866a-b7fa388cf5b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityCentralIndexKey_2c9a68d4-5d2e-4024-866a-b7fa388cf5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f45c1f8d-82d5-4a94-9c14-4cbabf3bc974" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f45c1f8d-82d5-4a94-9c14-4cbabf3bc974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_780ab4b4-2f7a-4beb-b210-1b12c3135b13" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityFileNumber_780ab4b4-2f7a-4beb-b210-1b12c3135b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_248a4973-17d4-4c93-8859-09ccf4d9d1a3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityTaxIdentificationNumber_248a4973-17d4-4c93-8859-09ccf4d9d1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_73a2babf-8cbf-4a8d-a4b0-f0971a06d940" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityAddressAddressLine1_73a2babf-8cbf-4a8d-a4b0-f0971a06d940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1ab7d786-63cc-42af-aea3-5669d01e3301" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityAddressAddressLine2_1ab7d786-63cc-42af-aea3-5669d01e3301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b0bcc970-cb43-43c6-9f9b-e67544ba977a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityAddressCityOrTown_b0bcc970-cb43-43c6-9f9b-e67544ba977a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_27846bd3-a181-433b-b9c1-373c79182391" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityAddressStateOrProvince_27846bd3-a181-433b-b9c1-373c79182391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_be26d2b6-b0a6-45bc-ac75-bc7ad235e39c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityAddressPostalZipCode_be26d2b6-b0a6-45bc-ac75-bc7ad235e39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2e017729-7483-4f4d-94b0-cf05c6ae567b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_CityAreaCode_2e017729-7483-4f4d-94b0-cf05c6ae567b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e4860c3c-f280-427f-bd30-6f3263373652" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_LocalPhoneNumber_e4860c3c-f280-427f-bd30-6f3263373652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_3dbad467-f112-46b5-ac60-1de48aaabc9e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_WrittenCommunications_3dbad467-f112-46b5-ac60-1de48aaabc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_2e29f5be-bf04-4ec1-9eae-6a16a7d49354" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_SolicitingMaterial_2e29f5be-bf04-4ec1-9eae-6a16a7d49354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_36a17600-7969-47d3-897b-a6a43dab78c3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_PreCommencementTenderOffer_36a17600-7969-47d3-897b-a6a43dab78c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ac966f0d-8528-45cb-8fa2-9d9ca09d1687" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ac966f0d-8528-45cb-8fa2-9d9ca09d1687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3a20151a-14fa-4fde-bca2-06e625202999" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_Security12bTitle_3a20151a-14fa-4fde-bca2-06e625202999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2ca9dbba-87a0-434a-8aaf-f945cd6a8f16" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_TradingSymbol_2ca9dbba-87a0-434a-8aaf-f945cd6a8f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e288feb2-369d-4ef4-8de4-51d1b7d8c8bd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_SecurityExchangeName_e288feb2-369d-4ef4-8de4-51d1b7d8c8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_951e94bc-01e1-47e1-bd5d-bdfae04de956" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d75ccd8d-fc1e-4945-bc3c-bf414f64ba89" xlink:to="loc_dei_EntityEmergingGrowthCompany_951e94bc-01e1-47e1-bd5d-bdfae04de956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "' 5P# 2(  A$! Q$!_\0
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MM-<T^"^L)UN+6=0Z2+GD>GL>H(/(YIN.ET9*:;Y'N:-%%)2-1:*** "BBB@
MHHHH **** &?A1CFEZ 5QWQ"^)&G?#^QC,J/?:I<GR[+3;?F:XD/  '.!G&3
MCOW. 2]MS*I4C3CS39L^(O$EGX9LTGNV9I)'$4%O$,RSR-]V-%[L?R'). "0
M[1;>]>/[3J(6.ZD&1;QL62!3_#G^(^K<>PQ7+>!?!NI?;CXG\5RK<>(ITVQV
MZ',.GQG_ )9Q^YXW-WQZ<GT"EJ12<JGOR5NP4M%%,Z HHHH **** "BBB@ H
MKXWOO^"JWP4TV^N+2:'Q/YL$K1/MTV,C<I(.#YO3(J#_ (>Q_!#_ )X^*/\
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MQG2YM9UW1RH>"/\ 'KD=JNI3Y?>CLS#"XKVS=.>DUNOU]#1HJ!9D:9D#J9%
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M%% !7/\ CKQCIOP[\&:YXGUB4Q:7H]E-?7+*,MY<:EB%'=CC '<D5T%?GO\
M\%</CB?#O@+0OA?IUSMO?$$@U'5$4@D6<+_ND8%>DDR[@5((^SD=&H _,SXE
M_$#5/BI\0/$/B_6I"^I:U>R7DPW,RQ[V)6-23D(B[54$\*JBJW@?QEJ?P[\9
M:'XHT:7R-5T>\AOK9R,CS(W# ,.ZDC!!Z@D5W/[+GP7G^/\ \=/"W@U4D.GW
M-SY^I3(&'E6<0WS,6"G:2JE%)&-[H.]2_M5_!.?]G_X[>*/"'DR)ID-Q]JTJ
M60-B6RE^>$AB!O*J3&S 8WQN.U '[N?#'X@:9\5?A[X>\7:.V=.UFRCO(E+
MF/<H+(V/XD;*GW4UU-?G/_P2+^.AU/PWXA^%.I7&9]+8ZOI(=LG[/(P6XB [
M!)65^N29W]*_1F@#)\0:#9^)M'N--OXO-MKA=K+W'<$'L00"/<5\]:5K>L_
M/Q@^EWQ>\T.9M^U>CH?^6B9Z..Z_SX:OI@5R?Q$\!6?C_07LYU$=S'E[>Y[Q
MOC]0>X_J 1U4*JC[D_A9XN88.=5>WP[M4CMY^0FL6,7CG0[?5-"U/[+?A-]E
MJ-O@XSU1U(^9"1\R,.W9@".<\'?&:*YUM_#/BJ!-!\30N(C&S?N+ECC!C8_W
MN,*?48)YKR+P/XZU?X0^([C2M2CD-DLNRZM#U0_WT]R,'T88]B/7?B5\.](^
M-7A6"^T^XB%^J;[*_49!]4?C.W/XJ>W!!C$8>5)\T=F<&'Q\\5!SHZ5(_%%]
M3U!6#+D<BBOD_P "_'7Q#\+]6D\.>+X)[RTM7\IO,YN+?N,-_P M%(.1ST(P
M<#%?3?AWQ-I?BO3(M0TJ\BO;23I)&>AQT(Z@^H/(KDC-2/5PF84L6K+22W3W
M-8>]1R2K&I9R%4#))/ JMJFJ6NC6,]Y>W$=M;0KN>65MJJOJ37R3\:/CW=^.
MIIM)T:22S\/KE7?[LEU[MZ)_L^G7K@$YJ"NQ8_,:6!A>6LGLCI?C9^T0UY)/
MH?A.Y9(!E+C5(CR_JL1]/]L=>W')U?@!\!_[/%OXG\1V_P#II DLK&0?ZGN)
M'']_T'\/7[WW<_\ 9\^!IN/L_BGQ!;?NQB2QLY1U])&'ITVC\?2OH'Q)XFT[
MPCI<E_J5PMO G"CJSMV51W/!_6HIPE-J4CQ\)AYXB7U['.RZ+HC0N+F&QMVF
MGD2"&,9>21@JJ!U))[4^&3S(T<;L,,@,I4\\\@CBO.O!TFH_$;4%\0ZG$UGH
M4+;M,TYCDR,#Q/)CJ<CY1T'4= Q])QMZ5TSCRZ,^DH5?;1YDM.A^67_!8_\
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M ##(Z$5[C^S;^VEXJ_9W\"7OAK1IHUL[C49+\K+"KD,T<:'!(X'[L?F:\/\
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M:E:0W5K*LT$JATD0Y!4C((/TI8BC[-WCK%['OY;COK<.2II..Z/RZ_X+'_\
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ME>S''0,.K>F O]X=C;>$;_XKZQ;ZUXJMI+3P]:MYFGZ!-UD/:6Y7U/\ <.<
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7W;L<^M.HHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  05,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRAXIS PRECISION MEDICINES,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001689548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5195942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">99 High Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">30th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-8460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.0001&#160;par value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRAX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="prax-20251105.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="prax-20251105.htm">prax-20251105.htm</File>
    <File>prax-20251105.xsd</File>
    <File>prax-20251105_lab.xml</File>
    <File>prax-20251105_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "prax-20251105.htm": {
   "nsprefix": "prax",
   "nsuri": "http://praxismedicines.com/20251105",
   "dts": {
    "inline": {
     "local": [
      "prax-20251105.htm"
     ]
    },
    "schema": {
     "local": [
      "prax-20251105.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "prax-20251105_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prax-20251105_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://praxismedicines.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prax-20251105.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prax-20251105.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001689548-25-000110-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001689548-25-000110-xbrl.zip
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MT"5JPM"=3A:'JP!L8-T4]VA@T(#?A@TD4/HY!=NMFU:MBI KH(_RLXE3I$Q
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ML4Y:F<&#)_OD(Q E!"7IH8<!!'M0GB(E(2I=[/YMK&_S((ER[C$P]!J*DI6
M89)S$,)X5NX7Z_,) K0\!<V.1I3R$%4Q?(07V;2XDR+1"QJ,1<CE$,:FZ'P,
M>9\KXKJFC?I9>Q>ML1"X[Y)>GP-X8ADCP0K&!007FF5XOJ=%1N>8A[,[G]'U
MF_'VS-=:H@;R]@+5J%+40W*"T\FPG'-(@T ;VSX#IQ((CZ8R8(E9!6,81Y)I
MB4F-(;'K.=W"8UPR.DHX8WXIYAO/&"X[UGL/UIK(<?\O=/OU&C,2<-KG03*3
MGILJ(A-PC@%VD6*15I7R>5P>CM[" _@?LYN2D7S8(2U:?;04+7.?H]4-NF-,
M@0''(YYLHCD;*V*90MJ!%P+3I;??>(OSRK$'/DHZ]1H6S'D1<76= L;HR@"C
M):BG&G(\ JZ=+IGGU5L\\++#W6CFQ):YIF6;<TI8'Q%+=, <!\M< <1.9//(
M_SB#DFS3^7N1A[!_SM\+;VNIF';E:><O?^5(K5Q]E9'J=;-N;>NNEGT\1_Y(
M!)UP_P:; ;N'^3(R?\@-JJUO4[TM4I^8] 2/%^[YF-MYR0#)^E2>.,Z4*C9M
M\Q8.*9WD/.BTV7FH//-LHZSL99IA,-B&<7QJA^V4KG5;6*)+3G8)&WGXR0TN
MOY4PEHF%.50CO'_ M$^+=/M7'.TD9;0MY3'CS /_?2?_7>L8NIO$T,?$U['-
MZ@VM:QET:R= 7]KLM;?/1]SW _;VPF-;Y0UD)B>5<HK6KG!N <\)<DTA'.[@
M6H#LX#43GZBB1-^H=(0LZ?OI[Z)!Y*MT#@-'(OKWT_ST?N(7E+7FSF9^7[?Y
M7_6)HV3GH2%80!'5E=_Y>;#_2:3]T(7VP0D8J]4NS_TTT,9I 7>6%AB*!X:Z
M949?,/K5H -8J08-[NE4(@?.DVA;OV+T!L4^.7,.O<ZOE^<WOW?;JU'ZNNTT
M9Q?)A/D[VY,=LF]C+M)\2-[<VYJM-7\<3(E'Q[@=II.%R97B.$T?0G]8%O@0
M);<T]]F0!@-,8>% VBRE#3!Q. ZACQZ.CM4P$H"<;Q[R'EO+>Y1=LU)^G8,N
M)=-Q-DM\/%7L_3HPE1W3K3FOD4)9:U?=]W6@Y/'KX4ER,_SWA<!;]N>V[O;E
MBGKS75O]]HN+/[_0F/GJB;J:.>S;B29WPL2_3!L[\X9W@G!1%K%(S>,1Z47C
MO^DZ*=TKB7P^0[7/Y'Y7I'XGZ9_6D+,!>)/9;8%7^K9 L4%DMB>Q4C'Y.6+]
M&\;-_P=02P,$%     @ =D!E6^&4IC)A @   @<  !$   !P<F%X+3(P,C4Q
M,3 U+GAS9,U46V_:,!1^YU=X>9YS P9!A4IK56D2NZAKM;Y-CG,"5AT[LYU"
M_WUM$X]2UFKL:7FRS_F^<_-W<G:^;3AZ *69%/,HB],(@:"R8F(UCVYOKO T
M.E\,!F?O,+[[>+U$EY)V#0B#+A00 Q7:,+-&9@WHAU3W[(&@;YR86JH&XX6G
M7<CV4;'5VJ \S<<!%KQJ1D9U1N##!%?%=(I'=3["!(937$_R<0$T'Q43\GXU
MFT[2E$)!\;": AZ1<8[+NBPQS<=54=06248^Z%;/-%U#0Y!M3>C95L^CM3'M
M+$DVFTV\&<92K9(\3;/D[O/RNX=&/98S<7^ WI:*!_PP<>Z2: CP5I'M;[B[
M,-U Q2@3H&,JF\1UG&7I.$+$&,7*SL"5'<TEU*3C9AYUXE='.*L95';N'-QD
M#P#/W(:H%9@OI '=$@I_EW<Q0,A-A#6M5 :)(_9QDTQH0P2U3>[&N)24&*^.
M5RGNA@,/.Q/.<CS,XJVNHN0?:M@/^K0: N_T&GPP#31>R8>D N9'^.?T^C6X
M.V!W.,Q)A)#&\YVEM[4M$[7<&:S)%3X+U5]#';1[),A>OEE1%(GW6BUZ,E%4
M20YO@ZU89 O*,-#/Q>P#K!74\\BI"0?Y_&P5Q+:2 #E*</@$SFTS@+8J]OTN
M]PV%$.:QM2&T?0<.NQ']S_US4I[:OZ4 /[%Q1[RQ?L2J>70A[>\X0LYV>_WI
MS37W"7?X$#"$K*!F@GG1I?[+$-[_O#'RK+/D)?9%E$Y#]54L_/GEP_;D'O(&
MD1)..WXZ;U_6J[3>&.;7[U=RN&"[^[,E](;=9B\&3U!+ P04    " !V0&5;
MA]T+9T *   46   %0   '!R87@M,C R-3$Q,#5?;&%B+GAM;,6<76_;.!:&
M[_LKM-F;76!82Y1(D46;03?3#HK-M$&38@:[6!C\3(3:5B K3?+OEY3M5(IE
M6:1LY:9U;/J\YSW6HW,D2W[[Z\-\%OQ0Q3++%^].HM?A2: 6(I?9XOK=R;>K
MCX"<_'KZZM7;OP'PU[^^G@>_Y>)NKA9E<%8H5BH9W&?E35#>J.#/O/B>_6#!
MQ8R5.B_F )Q6;SO+;Q^+[/JF#& (T6;9YM7B#4MTQ!1.@:2$@$3#!# 5$Z!3
MB*@2,*$I^^7Z#4G#4"@J0"R) @E#$'#-.1 024JU6<F2*N@L6WQ_8__A;*D"
M8V^QK/Y\=W)3EK=O)I/[^_O7#[R8O<Z+ZPD,PWBR67VR7OZPM?X^KE9'E-))
M]>K3TF76MM"$C29__7%^*6[4G(%LL2S90EB!9?9F63UYG@M65E7?FU>P<X7]
M"VR6 ?L4B""(H]</2WER^BH(5N4H\IGZJG1@___V]=-.23JQ*R8+=6T_VPM5
M9+F\+%E1GC.N9B;[*EKY>*O>G2RS^>U,;9Z[*91N#SLKBD94FR6U64;89OGW
M76*3 >D?*-]R.]<#)%?9_7RH'+MJ^OE@Z5Z9/80Z?L(UF<$IKS:H#PLYUK;[
M)#4X]>-G?*C-(B_9;(3-XJ=,+>69?>+</%K+V$ =.]-*9[WKKJ6J'DJUD&JU
MMVR$#C+Y[L0\FDJ532_S62:RTK3%/TQ&1<9F4Z9I;#J0 IPA!!+(*"!:1T B
M@F0LN4HIFI9/6_14+<"WRXUXI= 5_L3!5;F#SD(M\[M"K/J:D;0]?97%Z4_!
M8*/X=O(S,^=BS(YL<78T=[EH1)W9MIP7STWD8H^)GQOYTKBH'"R5>'V=_YB8
M-T[L[&,? /N@VK9WA)MLE?Y]L<F0%6)/K=8K)B(WT\9M"1IETT4^[V.ES/M\
M:JMR&<&3("^D*LSTV))\8[OYL\A*0]M9/I_?+;+5^+.<Q@P32M,$8*H,1TR%
M@"0Q!&F:()+&$A*H^G+4JG!DE-::05.T/TWM5=D/U&"O;DPYVG3"JM.*%UGM
M$4>#J]-0G:_NA>Z(V:.*V<5-OE"?[^9<%5.!E" ("Z!U*$ 2HQ00BA5 $8,1
MPG$2LK0O7<^#'QFL2BZH](*58'^HMNJPGZ<A[MQ0<C#FA-$N!UX$;04;#9Y=
M-NK<[%SCCLQ9_D,5[_FR+)@H>VPGC?7'VT@JF>"_&Z'_'683:4W>:_MH1AIM
MXV@U4-\RVA>X;Q:;,UU/!W>_F0%H*L-8("HY8)HID.B8 XZ)&58HDDF*(HQ3
MWG=WVJIPY'WJT_F[E6A@5 ,KVW_/VEZ7_=@,=NN&C[-1)XPZS7CAU!YQ-*PZ
M#=7QZE[HCME%H>SPHTR&-NR5/1@OOFAM6C8C@E%MCJV%PAHDB3TP()$&J:0(
MAK'&F,*^K.V6.3)P1AB(FG*PD@XJ[?[4=91I/WJ',>_&GY]O)PCWV_(BL2/L
M:#CNMU9GLL=J=S _+,JL?#PS\0HV^V0B/OQ;/4Y3K'E"D 0BP1%("". 2)D"
M&D=:"IF$/.G-9*O"D7%<:09KT:!2#8QL?Q+;Z[(?PL%NW?AS-NJ$7J<9+^K:
M(XX&7*>A.FO="]TQ>V^(E9;:CS-V;<9+*3&C E"(#%Y00L"25 ,.6<1(C)B
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M*=CH0^5S&VT#Y=8:W\[Y7DKSL2TK*+\4%T7^(S.)3B$-26R.U0 2W+3,&$I
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M.SSRE59&!$\ O(ZW)!GYV?,!( #YZ#D/L='TKC[6H0C%-$P6 /[]4?> G2]
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MT04C6@>.KD298L ^'SP(Q=C]G$"Z \6DP@W ?GF+[:_K[&Z."FX@H*(HS8,
ML[W@/T@LS$D[I!T9[=00_3RZ+!UPS\FZ\6F<,AQOV+LC+_?SY2(_#-O[Z2KH
M4*-)U<(B?C6G K"B)+[&4(D\^G<6*(5- +G>:A?U1=:MO">0:)GO1,V@:YX
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M##KKBJ(PWHKNX:P\NLZ@@RD+'_-1N4>I5K**;R@;X05/O*B6JF9K16MN^E3
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M,3 U+FAT;5!+ 0(4 Q0    ( '9 95OAE*8R80(   ('   1
M  "  3$0  !P<F%X+3(P,C4Q,3 U+GAS9%!+ 0(4 Q0    ( '9 95N'W0MG
M0 H  !18   5              "  <$2  !P<F%X+3(P,C4Q,3 U7VQA8BYX
M;6Q02P$"% ,4    " !V0&5;E;PS9MP&  #^,@  %0              @ $T
M'0  <')A>"TR,#(U,3$P-5]P<F4N>&UL4$L! A0#%     @ =D!E6T.DFEV^
M)@  NU\! !(              ( !0R0  '!R87AI<W$S,C R-7!R+FAT;5!+
4!08     !0 % $0!   Q2P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>prax-20251105_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prax-20251105.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2025-11-05</startDate>
            <endDate>2025-11-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001689548</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">PRAXIS PRECISION MEDICINES,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39620</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-5195942</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">99 High Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">30th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">300-8460</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common&#160;Stock,&#160;$0.0001&#160;par value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">PRAX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
